Though the signature was only significantly associated with ICI-related biomarkers like TNFRSF9, instead of CTLA4, LAG3, HAVCR2 and PDCD1, thus proving that the efficacy of immunotherapy still presents an underprivileged position within the treatment of bladder cancer. The gene discussed is TNFRSF9; the disease is urinary bladder carcinoma.